1 / 58

Pharmacologic Considerations in the Cardiac Patient

Pharmacologic Considerations in the Cardiac Patient. Wayne E. Ellis, Ph.D., CRNA. Treatment of Ischemia(primary). ASA 325 mg immediately Thrombolytics (Retevase) > flow rate than TPA 2 doses @ 30 min intervals lyse clots through the activation of plasminogen. Primary Treatment.

rhona
Download Presentation

Pharmacologic Considerations in the Cardiac Patient

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmacologic Considerations in the Cardiac Patient Wayne E. Ellis, Ph.D., CRNA

  2. Treatment of Ischemia(primary) • ASA 325 mg immediately • Thrombolytics (Retevase) • > flow rate than TPA • 2 doses @ 30 min intervals • lyse clots through the activation of plasminogen

  3. Primary Treatment • Antiplatelet agents(abciximab, eptifibatide, tirofiban, integullin) • GPIIb-IIIa antagonists • inhibit platelet function by blocking the GPIIb-IIIa receptor, the final pathway of platelet aggregation • thereby decreasing thrombi development and prevents arterial vessel occlusion

  4. Percutaneous Coronary Intervention • Advantages include: higher recanulazation rates • improved blood flow through the infarct-related vessel • improved LV function • lower in-hospital mortality rates

  5. Anesthetic Technique Goals of Anesthesia loss of consciousness amnesia analgesia suppression of reflexes (endocrine and autonomic) muscle relaxation

  6. Preoperative Preparation Angina Medications to control it Blood pressure controlled Diastolic < 95 torr Congestive heart failure treated Diuretics Afterload reduction Bed rest if indicated Control diabetes

  7. Preoperative Medications Sedation Prevent tachycardia Hypertension Prepared for hypoxia Supplemental oxygen Calcium channel blockers not protective of perioperative ischemia Antihypertensives continue on day of surgery Stop Diuretics

  8. Enoxaparin, Dalteparin Anticoagulant activity by binding to antithrombin III, which further binds and inactivates the coagulation factors IIa (thrombin) and Xa Advantages include dosed per body wt. Given q12 sub q. Less trombocytopenia and bleeding Low Molecular Weight Heparin

  9. Opioids • Advantage relates to the relative lack of myocardial depression • Exception Sufenta, Carfentanil, and high dose fentanyl • They maintain stable hemodynamics and reduce heart rate • A primary opioid technique may be of value in the patient with severe myocardial dysfunction

  10. Opioids Advantages Excellent analgesia Hemodynamic stability Blunt reflexes Can use 100% oxygen

  11. Opioids Disadvantages May not block hemodynamic and hormonal responses in patients with good LV function Do not ensure amnesia Chest wall rigidity Respiratory depression

  12. Vasoconstrictors • are useful in the prevention and treatment of ischemia r/t the ability to increase systemic BP • Phenylephrine improves coronary perfusion pressure, at the expense of increasing afterload and Mv02

  13. Vasoconstrictors • At the same time, phenylephrine causes venoconstriction, increasing venous return and left ventricular preload. • The increase in CPP more than offsets the increase in wall tension

  14. Inhalation Agents Advantages Myocardial oxygen balance altered favorably by reductions in contractility and afterload Easily titratable Can be administered via CPB machine Rapidly eliminated

  15. Inhalational Agents • Disadvantages include myocardial depression • systemic hypotension with possible tachycardia • lack of postoperative analgesia

  16. Inhalation Agents Disadvantages Significant hemodynamic variability May cause tachycardia or alter sinus node function Possibility of “coronary steal syndrome”

  17. Inhalation Agents Potential for coronary steal Alters coronary autoregulation Alters regional blood flow Little influence on outcome

  18. Coronary Steal Arteriolar dilation of normal vessels diverts blood away from stenotic areas Commonly associated with adenosine, dipyridamole, and SNP Forane causes steal and new ST-T segment depression May not be important since Forane reduces SVR, depresses the myocardium yet maintains CO

  19. Antianginal medications Beta-blockers Calcium Channel Blockers Nitrates Nitropaste morning of surgery WE Ellis

  20. Nitrates • Nitroglycerin = venodialator, reduces venous return, decreases wall tension(Mv02) also a coronary arterial dialator. • Drug of choice for coronary vasospasm • Although primarily is a systemic venodialator, at high doses causes arterial dilatation and systemic hypotension

  21. Cardioactive drugs Nitroglycerin Lower LVEDP Vasodilator Poor ventricular function

  22. Beta Blockers • Beta blockers reduce myocardial workload(Mv02), and oxygen consumption(V02) by reducing HR,BP, and contractility, and they increase the threshold for ventricular fibrillation. • Indications for beta blockers include: sinus tachycardia, supraventricular dysrhythmias and hyperdynamic states

  23. Beta Blockers Negative inotropic effects Withdrawal following stoppage of beta blocker Unstable angina Myocardial infarction

  24. Beta Blockers • Propranolol (non-selective) t1/2 = 4-6 hours • Metoprolol (B1 selective) t 1/2 = 4-6 hours • Labatelol (1:7 ratio) t 1/2 = 2-4hours • Esmolol (Beta1 selective) t1/2 = 9.5 minutes

  25. Esmolol Control heart rate and blood pressure Induction Emergence

  26. Labetalol Mixed alpha and beta Control hypertension Heart rate management

  27. Ca Channel Blockers • Evidence for beneficial effects post mi is less compelling • Nifedipine treatment is associated with a trend towards increased mortality and reinfarction • Verapamil does not reduce mortality or reinfarction • Verapamil - useful for slowing the ventricular response in atrial fibrillation/flutter

  28. Ca Channel Blockers • Cardizem- in pt’s with non-Q wave infarction seems to reduce the reinfarction rate during the 1st 6 months after the infarction, but incidence of late infarction was similar to a placebo. • Cardizem increases cardiac events in pt’s with LVEF<40% , but decreases their incidence in pt’s with preserved LV function

  29. Ca Channel Blockers • All Ca blockers depress contractility, reduce coronary and systemic tone, decrease sino-atrial node firing, and impede atrioventricular conduction. • The negative inatropic effect is greatest with verapamil • Nifedipine + Cardizem are used in the prevention of coronary vasospasm

  30. Nifedipine Controlling hypertension Manage coronary artery spasm

  31. ACE Inhibitors • Are effective in reducing ischemic effects after MI • Treatment should be instituted within the 1st 24 hours of all pt’s with acute mi complicated by symptomatic or asymptomatic left ventricular dysfunction

  32. ACE Inhibitors • Contraindicated in pt’s with hypotension, bilateral renal artery stenosis, history of a cough or angio-edema with ace inhibitors

  33. Aspirin • ASA benefit well established as a secondary prevention • Antiplatelet therapeutic dose (75-325mg/day) • other antiplatelet agents such as dipyridamole are not supported in the literature except in pt’s with allergies to ASA who are poor candidates to oral anticoagulants

  34. Anticoagulants • Studies of anticoagulant treatment after mi show reduction in death, recurrent MI, and thromboembolitic complications • However, trials comparing warafin to ASA for secondary prevention show no difference in recurrent infarction or death

  35. Anticoagulants • Are indicated for pt’s with ASA intolerance and for those at risk of embolisation from left ventricular or atrial clot(i.e. persistent atrial fib)

  36. Lipid Lowering Agents • meta analysis of clinical trials show that lipid lowering agents produce a reduction in fatal and non-fatal MI’s and cardiovascular deaths • Should be given to pt’s with LDL concentration >3.37 mmol/1

  37. Clonidine Less hypertension Decreased anesthesia requirements

  38. Anesthetic Management Regional vs. general Anesthetic management skills more important than technique Safest technique is the one the practitioner does best

  39. Regional Anesthesia Monitor patient more accurately Control sympathetic responses Fluids Esmolol

  40. General anesthesia Avoids sympathectomy Risks with intubation Sympathetic stimulation Hypoxia Increased catecholamines Loss of subjective monitor Chest pain Ischemia

  41. General Anesthesia required Narcotics Effective control of catecholamines Respiratory depression Prolonged ventilation

  42. Lidocaine Blunt effects of intubation 1.5 mg/kg 4-6 minutes prior to intubation

  43. Nitrous Oxide Rarely used due to: increased PVR depression of myocardial contractility mild increase in SVR air expansion

  44. Induction Drugs Barbiturates Benzodiazepines Ketamine Etomidate

  45. Avoid Ketamine Hypertension Tachycardia Use in trauma

  46. Etomidate Painful to inject More CV stability

  47. Barbiturate Direct depressant Extended duration of activity Smaller doses 1-2 mg/kg Add benzodiazepines and narcotic

  48. Benzodiazepines Quell anxiety Hemodynamic stability Extended duration of action Potential for hypoxia Lidocaine Esmolol

  49. Muscle Relaxants Used to: facilitate intubation prevent shivering attenuate skeletal muscle contraction during defibrillation

More Related